ASCO Highlights

flipper_slider

Editor's Choice

Prof. Martin Reck explains the latest data from the CheckMate 017 and 057 trials of nivolumab in NSCLC. He also discusses new strategies for immunotherapy is NSCLC. FILMED AT THE AMERICAN SOCIETY OF CLINICAL...

ASCO Highlights Videos

Part 2 of 2 - Dr Ajjai Alva explains checkpoint inhibitors and discusses their use in combination with IL-2 for patients who do not respond to checkpoint inhibitors alone. Filmed at The American Society of Clinical Oncology (ASCO) meeting, 2017
Part 2 of 2 - Dr David Heigener discusses the large number of patients that can’t receive targeted therapy or checkpoint inhibitors, and other unmet needs in non-small cell lung cancer (NSCLC). He also gives us his thoughts on liquid biopsy and its use in NSCLC. Filmed at The American Society of...
Part 1 of 2 – The first part of our interview with Dr David Heigener highlights the lack of data on combination therapies for EGFR-positive non-small cell lung cancer and the issues with synergistic toxicity. Filmed at The American Society of Clinical Oncology (ASCO) meeting, 2017
Dr Andrew Hendifar reviews the adverse events associated with PEGPH20 (pegvorhyaluronidase alfa), and the future application of PEGPH20 in different cancers This video was supported by Halozyme. Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, US, June 2017...
Dr Andrew Hendifar discusses targeting tumor hyaluronan with PEGPH20 (pegvorhyaluronidase alfa) in preclinical models and in human tissue. He discusses the results of the recent phase II study of PEGPH20 in combination with gemcitabine and nab-paclitaxel. This video was supported by Halozyme...
Dr Andrea Bullock explains the role of hyaluronic acid in the peritumoral stroma of pancreatic cancer. She also explains how hyaluronidase works against hyaluronan to normalize blood flow to the tumor. Finally she discusses the longer half-life of the pegylated version (PEGPH20; pegvorhyaluronidase...
Dr Andrea Bullock summarizes the difficulties in diagnosing and treating pancreatic cancer, and the composition of the tumor cells in pancreatic cancer. This video was supported by Halozyme. Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, US, June 2017
Part 3 of 3 - Dr Domenica Lorusso tells us which presentations, in gynecological cancer, she has found particularly interesting at ASCO 2017. Speaker disclosures: Advisory Board for Clovis Oncology, Astra Zeneca, PharmaMar, Roche. Filmed at the American Society of Clinical Oncology (ASCO)...
Part 2 of 3 – Dr Domenica Lorusso discusses the ICON 6 trial and the difficulties in analyzing survival benefits in ovarian cancer patients. She also discusses the ANTHALYA study and toxicity of bevacizumab. Speaker disclosures: Advisory Board for Clovis Oncology, Astra Zeneca, PharmaMar, Roche...
Part 1 of 3 – Dr Domenica Lorusso discusses the results of the phase III LION study and the DESKTOP III trial in ovarian cancer. Speaker disclosures: Advisory Board for Clovis Oncology, Astra Zeneca, PharmaMar, Roche. Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting,...
Jeff Evans discusses the key findings from the phase III REFLECT study, and how these results might impact the future management of liver cancer patients. Speaker disclosures: Consultancy for Eisai for Advisory Boards. Support for clinical trials (all payments to university). Filmed at the...
Part 2 of 2 – Dr Marc Peeters, from our European Editorial Board, explains the move from treating patients with BRAF-targeting drugs, to using combination therapy to target the EGFR pathway in BRAF-mutant mCRC. He also discusses the BEACON CRC study, which uses this combination of binimetinib,...
Part 1 of 2 – Dr Marc Peeters, from our European Editorial Board, summarizes the clinical use of circulating tumor DNA in colorectal cancer (CRC). He also discusses the difficulties of making interstudy comparisons between the outcomes of second-line trials in metastatic CRC. Speaker disclosures...
Part 2 of 2 - Dr Maurice Pérol talks to us about the recent IFCT-GFPC 0502-Eco phase III study in optimization of maintenance therapy in non-small cell lung cancer, by tailoring the treatment according to the response from induction chemotherapy. Filmed at the American Society of Clinical...
Part 1 of 2 – Dr Maurice Pérol discusses the use of programmed death-ligand 1 (PD-L1) as a predictive biomarker in non-small cell lung cancer. Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, US, June 2017